新型可生物降解医用高分子材料-聚膦腈

聚磷腈是一族由交替的氮、磷原子以交替的单键、双键构成无机主链的新型可生物降解聚合物。聚膦腈具有独特的性质和显著的合成多样性,降解产物为磷酸、氨、氨基酸和乙醇等无毒物质。通过改变聚膦腈侧链结构和组成,可调节聚膦腈的降解速度,控制药物释放的速度。本文主要综述了聚膦腈的合成、降解及其在药物控释系统中的应用。     

生物可降解聚膦腈材料的功能化及研究进展

聚膦腈是一类主链由磷氮原子交替组成,每个磷原子带有两个有机官能团侧基的有机-无机杂化高分子,其化学结构强大的可设计性赋予了材料丰富的理化性能。作为生物学用途的聚膦腈材料,生物相容性、生物可降解性和功能化改性是实现其应用的关键因素。本文从数种功能化聚膦腈(如光致荧光、导电、聚膦腈-聚酯共聚物)的制备、聚膦腈的降解机理和降解行为调控,以及生物可降解聚膦腈作为组织工程支架材料、药物载体材料和基因转染材料等几个方面,较为全面地综述了聚膦腈生物医用高分子的研究进展。     

聚膦腈/聚酸酐共混物的相容性和水解行为

采用溶液混合法制备了聚 [(双 甘氨酸乙酯 )膦腈 ](PGP)与聚酸酐 (PSA或PSTP)的共聚物 .利用示差扫描量热仪和相差显微镜研究了两体系的共混相容性 ,发现PGP与PSTP具有部分相容性 .体外降解试验表明 ,PGP PSTP降解行为呈均一性 ,且由于PSTP酸性产物的催化作用 ,降解速度明显较PGP加快 (约 15天 )并随PSTP含量增加而加快 .PGP PSTP有望成为一种新型的药物控释载体材料     

温敏性聚膦腈及其在药物释放体系中的应用

温敏性聚合物能通过感知温度而实现环境响应,作为药剂可依靠对此类信号的自反馈响应而释放药物或中止释放,极大地增强了释药的持续性和专一性,从而提高了药物的药效和安全性.温敏性聚膦腈是一类新型的温敏材料,它具有良好的生物可降解性质,优良的生物相容性.因此,温敏性聚膦腈作为药物载体用于药物释放体系具有很好的应用前景,近年来备受关注.本文对聚膦腈的温敏性质、生物降解性质进行了评述,并探讨了LCST的影响因素,以及在药物释放体系的应用进展.     

直链淀粉交联氨基酸酯取代聚膦腈杂化材料的制备

利用直链淀粉与甘/丙氨酸乙酯共取代聚膦腈交联, 制得了一种具有网络结构的新型杂化材料. 实验结果表明, 淀粉衍生物上的羟基转变为醇钠后, 可与聚膦腈分子链上的P-Cl键发生亲核取代反应; 所得聚合物膜无明显相分离, 力学性能优于具有相似组成的直链淀粉/聚膦腈共混膜, 表面亲水性和吸水率与对应的共混膜接近, 且均高于纯聚膦腈膜. 因此, 该聚合物可作为杂化生物材料用于药物控制释放和组织工程方面的研究.     

高热稳定性聚膦腈亚微米球的室温快速合成

以六氯环三膦腈（HCCP）和4,4′-二羟基二苯砜（BPS）为共缩聚单体,乙腈为溶剂,三乙胺为缚酸剂,在室温条件下,采用沉淀聚合的方法快速合成了一种聚膦腈亚微米球。 红外光谱、元素分析及X射线能谱分析(EDX)测试表明,该聚膦腈亚微米球具有高度交联的化学结构;扫描电子显微镜和透射电子显微镜测试表明,该聚膦腈亚微米球粒径分布在410 nm附近,而且具有光滑的表面和实心的结构;热重分析(TGA)测试表明,该聚膦腈亚微米球的热分解温度达到531 ℃。 并推测了该聚膦腈亚微米球的形成机理。     

交联聚膦腈中空微球的可控制备

以分散聚合法制备的聚苯乙烯微球为模板,以六氯环三膦腈、4,4’-二羟基二苯砜为共聚单体,三乙胺为缚酸剂,室温条件下制备出了聚苯乙烯／聚膦腈（核／壳）复合微球,然后用四氢呋喃处理该复合微球,得到聚膦腈中空微球。利用红外光谱、元素分析、扫描电镜及投射电镜对所制备中空微球的结构及形貌进行了表征。结果表明,所制备聚膦腈中空微球...     

聚膦腈-g-聚己内酯共聚物的合成与表征

通过三甲基碘硅烷与聚二(2-甲氧基乙氧基)膦腈侧链上的醚键反应后水解得到侧链含部分羟基的聚膦腈,然后利用聚膦腈的侧链羟基在异辛酸亚锡催化作用下,引发己内酯单体开环聚合制备了聚膦腈-g-聚己内酯共聚物.该共聚物中聚己内酯链段的接枝率和侧链长度可通过改变三甲基碘硅烷和己内酯单体的投料来控制.     

以环三膦腈为核的非线性聚磷腈高分子

综述了近十多年来以环三膦腈为核的非线性聚膦腈高分子的合成、性能及其应用。重点介绍了直接亲核取代法与多官能团引发剂法在合成以环三膦腈为核的星形高分子中的应用,以及发散法与收敛法在合成以环三膦腈为核的树形高分子中的应用。简要阐述了以环三膦腈为核的星形、树形高分子在光电材料、生物医用材料等方面的应用,并展望了以环三膦腈为核的非线性聚膦腈高分子的发展趋势和方向。     

聚电解质复合物在药物控释中的应用

近年来聚电解质复合物在药物控释领域受到重视。对聚电解质复合物在响应型药物控释、细胞免疫隔离移植、多肽蛋白质药物的缓释及其基因治疗等领域的应用进行了综述。     

Pharmaceutical Applications of Ionic Liquids: A Personal Account

Ionic liquids (ILs) have been extensively used in drug formulation and delivery as designer solvents and other components because of their inherent tunability and useful physicochemical and biopharmaceutical properties. ILs can be used to manage some of the operational and functional challenges of drug delivery, including drug solubility, permeability, formulation instability, and in vivo systemic toxicity, that are associated with conventional organic solvents/agents. Furthermore, ILs have been recognized as potential solvents to address the polymorphism, limited solubility, poor permeability, instability, and low bioavailability of crystalline drugs. In this account, we discuss the technological progress and strategies toward designing biocompatible ILs and explore potential biomedical applications, namely the solubilization of small and macromolecular drugs, the creation of active pharmaceutical ingredients, and the delivery of pharmaceuticals.     

Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFR

Targeting acquired drug resistance represents the major challenge in the treatment of EGFR‐driven non‐small‐cell lung cancer (NSCLC). Herein, we describe the structure‐based design, synthesis, and biological evaluation of a novel class of covalent EGFR inhibitors that exhibit excellent inhibition of EGFR‐mutant drug‐resistant cells. Protein X‐ray crystallography combined with detailed kinetic studies led to a deeper understanding of the mode of inhibition of EGFR‐T790M and provided insight into the key principles for effective inhibition of the recently discovered tertiary mutation at EGFR‐C797S.     

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?

Despite enormous progress in the treatment of many malignancies, the development of cancer resistance is still an important reason for cancer chemotherapy failure. Increasing knowledge of cancers’ molecular complexity and mechanisms of their resistance to anticancer drugs, as well as extensive clinical experience, indicate that an effective fight against cancer requires a multidimensional approach. Multi-target chemotherapy may be achieved using drugs combination, co-delivery of medicines, or designing hybrid drugs. Hybrid drugs simultaneously targeting many points of signaling networks and various structures within a cancer cell have been extensively explored in recent years. The single hybrid agent can modulate multiple targets involved in cancer cell proliferation, possesses a simpler pharmacokinetic profile to reduce the possibility of drug interactions occurrence, and facilitates the process of drug development. Moreover, a single medication is expected to enhance patient compliance due to a less complicated treatment regimen, as well as a diminished number of adverse reactions and toxicity in comparison to a combination of drugs. As a consequence, many efforts have been made to design hybrid molecules of different chemical structures and functions as a means to circumvent drug resistance. The enormous number of studies in this field encouraged us to review the available literature and present selected research results highlighting the possible role of hybrid drugs in overcoming cancer drug resistance.     

Recent Aspects of Pharmaceutical Application of Cyclodextrins

Because of the multi-functional characteristics and bioadaptability, cyclodextrin (CyD) is capable of alleviating the undesirable properties of drug molecules through the formation of inclusion complexes. This paper outlines the current application of natural and chemically modified CyDs in the various pharmaceutical formulations including peptide and protein drugs. Furthermore, potential use of CyD/drug conjugates in site-specific drug delivery is discussed.     

Surface-modulated and thermoresponsive polyphosphoesternanoparticles for enhanced intracellular drug delivery

The chemical structure of end groups influenced the phase transition temperature of thermoresponsive polymers. We demonstrated a strategy for the preparation of the pH/thermo-responsive polymeric nanoparticles via subtle modification of end groups of thermoresponsive polymer segments with a carboxyl group and revealed its potential application for enhanced intracellular drug delivery. By developing a polymeric nanoparticle composed of poly(aliphatic ester) as the inner core and thermoresponsive polyphosphoester as the outer shell, we showed that end groups of thermoresponsive polyphosphoester segments modified by carboxyl groups exhibited a pH/thermo-responsive behavior due to the hydrophilic to hydrophobic transitions of the end groups in response to the pH. Moreover, by encapsulating doxorubicin into the hydrophobic core of such pH/thermo-responsive polymer nanoparticles, their intracellular delivery and cytotoxicity to wild-type and drug-resistant tumor cells were significantly enhanced through the phase-transition-dependent drug release that was triggered by endosomal/lysosomal pH. This novel strategy and the multi-responsive polymer nanoparticles achieved by the subtle chain-terminal modification of thermoresponsive polymers provide a smart platform for biomedical applications.     

Four‐fold Channel‐Nicked Human Ferritin Nanocages for Active Drug Loading and pH‐Responsive Drug Release

Human ferritins are emerging platforms for non‐toxic protein‐based drug delivery, owing to their intrinsic or acquirable targeting abilities to cancer cells and hollow cage structures for drug loading. However, reliable strategies for high‐level drug encapsulation within ferritin cavities and prompt cellular drug release are still lacking. Ferritin nanocages were developed with partially opened hydrophobic channels, which provide stable routes for spontaneous and highly accumulated loading of Fe^II‐conjugated drugs as well as pH‐responsive rapid drug release at endoplasmic pH. Multiple cancer‐related compounds, such as doxorubicin, curcumin, and quercetin, were actively and heavily loaded onto the prepared nicked ferritin. Drugs on these minimally modified ferritins were effectively delivered inside cancer cells with high toxicity.     

胆汁酸为载体的肝靶向一氧化氮释放药物的设计与合成

新型肝靶向一氧化氮释放药物对许多肝脏疾病具有较好的治疗作用. 以胆酸和熊去氧胆酸作为药物的载体, 以氨基酸作为联接子, 以氨基酸的α羧基模拟胆酸或熊去氧胆酸分子24位羧基的负电性, 最大限度地保持胆酸或熊去氧胆酸的结构特征, 通过酰胺键将载体与一氧化氮供体硝酸酯偶联, 设计并合成了一系列新型肝靶向一氧化氮释放偶合物, 其结构经元素分析, IR, 1H NMR和MS光谱分析确证. 利用四氯化碳及对乙酰氨基酚所致小鼠急性肝损伤模型研究化合物对小鼠急性肝损伤的修复作用.     

Proteomics and Its Application in Biomarker Discovery and Drug Development

Proteomics is a research field aiming to characterize molecular and cellular dynamics in protein expression and function on a global level. The introduction of proteomics has been greatly broadening our view and accelerating our path in various medical researches. The most significant advantage of proteomics is its ability to examine a whole proteome or sub-proteome in a single experiment so that the protein alterations corresponding to a pathological or biochemical condition at a given time c…     

空心纳米磷酸钙载药体系的制备与表征

非离子表面活性剂Tween 80和PEG 6000在水溶液中以一定的比例混合可形成稳定的类磷脂囊泡结构,这些囊泡可以作为模板来合成磷酸钙纳米空球颗粒。所制备的磷酸钙材料的结构和形貌通过TEM,SEM,FTIR,XRD进行了表征,是尺寸为100～150 nm左右的无定形磷酸钙空心颗粒。磷酸钙具有良好的生物相容性,因此这些具有空心结构特征的磷酸钙可发展为理想的载药体系。我们以牛血清蛋白(BSA)为模型体系研究了材料的载药和释放性能,发现所获得的空心纳米磷酸钙不仅具有良好的蛋白质负载量而且还具有优异的可释放性,明显优于传统的羟基磷灰石体系。